Smarter, Faster, Better: Leveraging Artificial Intelligence in Oncology Market Research

Posted by Sonal Singh on Feb 28, 2019 1:27:59 PM

Aritra Das co-authored this blog post with Sonal Singh. 

The oncology market has become increasingly crowded and complex incredibly quickly. As an oncology market researcher, you might be feeling a lot of pressure to up the analytical sophistication in your research and capture nuanced decision-making, all while getting insights to your key stakeholders faster. Have you ever wondered how AI could help solve some of the burning challenges that you’re facing, and help you get robust answers to your questions quickly to help you keep up with the rapidly changing market? Here’s how AI can help.


>
Read More

Behind the Consultant Curtain: Leveraging Your Segment’s Strengths

Posted by Malik Kaman on Jan 8, 2018 8:00:00 AM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part two in a two-part series.

In our previous post, we discussed the four typical “segments” of oncology companies:

  1. Original Innovators: High prior oncology success, low commercial sophistication
  2. The Space Invaders: Low prior oncology success, high commercial sophistication
  3. The New Kids on the Block: Low prior oncology success, low commercial sophistication
  4. The Vanguard: High prior oncology success, high commercial sophistication

>
Read More

Going Beyond the Buzz of CAR-T Therapy

Posted by Robert Rovner on Dec 21, 2017 10:21:09 AM

There’s no doubt that chimeric antigen receptor T-cell (CAR-T) therapies have been generating increased interest over the past four years at the American Society of Hematology’s (ASH) Annual Meeting. In 2014, 34 abstracts on CAR-T therapies were presented at ASH, a number that more than tripled to 110 abstracts by 2016. This year, more than 140 CAR-T abstracts were presented to a packed Georgia World Congress Center in Atlanta. While some questions about this novel approach to cancer treatment remain unanswered, one thing is for certain: CAR-T therapies are here to stay. 


>
Read More

Upending the Treatment Paradigm in AML

Posted by Nathan Noll on Dec 19, 2017 9:40:13 AM

Sony introduced the Walkman in 1979. At the time, it was revolutionary, but when compared with the technology available today, it is woefully outmatched.


>
Read More

Multiple Myeloma at ASH 2017: Observations and Analysis

Posted by Josh Hattem on Dec 14, 2017 9:11:58 AM

There were 935 abstracts related to multiple myeloma accepted into the 2017 American Society of Hematology (ASH) Annual Meeting, or roughly one piece of new research for every 127 multiple myeloma patients in the U.S., according to the National Cancer Institute.


>
Read More